EHP is committed to developing novel therapies focused initially on the treatment of four autoimmune and neurodegenerative diseases with unmet medical needs. We have the following clinical trials underway. For eligibility criteria and additional study details, visit www.ClinicalTrials.gov.
Emerald Health Pharmaceuticals’ Clinical Programs
| Disease | Study Phase | Trial | Objective | Enrollment Status |
|---|---|---|---|---|
| Systemic Sclerosis
|
Phase IIa
|
EHP-101
Double-blind, randomized, intracohort placebo-controlled, multicenter study. |
To evaluate the safety, tolerability, and preliminary efficacy of EHP-101 in patients with diffuse cutaneous systemic sclerosis.
|
Active.
Enrolling in the United States, Australia and New Zealand.
|
| Multiple Sclerosis | Initiating Phase II | EHP-101
Open label study. |
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of EHP-101 in patients with relapsing forms of multiple sclerosis. | Enrollment scheduled to begin end of 2021. |